MedWatch

Biogen upgrades financial guidance after exceeding expectations in Q2

Halfway through the accounting year, Biogen predicts a higher revenue than previously expected.

Photo: BRIAN SNYDER/REUTERS / X90051

US firm Biogen has upgraded its guidance for the financial year and now predicts a higher revenue than originally expected, Bloomberg News writes based on the company's Q2 report.

The pharmaceutical company now predicts a revenue of between USD 10.65bn and USD 10.85bn, compared to its previous expectation of between USD 10.45bn and USD 10.75bn. The analyst consensus estimate was a USD 10.59bn revenue.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs